Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Balkan Med J ; 38(5): 278-286, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34462254

RESUMO

BACKGROUND: Nanomedicine has provided promising tools for the imaging, diagnosis, and treatment of cancer. Gold nanoparticles (GNPs) may be useful in enhancing the efficacy of radiotherapy, such as radiosensitization, in cancer therapy. AIMS: To develop a nanodrug complex containing cetuximab (C225,CTX) and cisplatin (CDDP) conjugated with GNPs and to investigate its cytotoxic effects on oral cavity cancer cells when combined with radiotherapy. STUDY DESIGN: In vitro cell culture study. METHODS: The GNPs were synthesized and successfully conjugated with cetuximab and cisplatin. Cell viability was monitored by the xCELLigence real-time cell analysis (RTCA) single-plate (SP) system in GNP-treated UPCI-SCC-131 cells for 48 hours. Cells with/without GNPs were irradiated with 6 MV X-rays, and colony formation was assayed to investigate the long-term effects of GNPs and the nanodrug complex after irradiation on radiotherapy-resistant oral cavity cancer cells. RESULTS: The GNPs entered the tumor cells, and GNP-CDDP (P <.0001) and GNP-CDDP-CTX (P < .0001) were shown to cause a decrease in cell viability. GNP and GNP-CTX combined with radiotherapy led to greater reduction on UPCI-SCC-131 colony numbers, than radiation alone (P = .0369) and radiation with free CTX, with sensitizing enhancement ratios of 1 : 2 and 1 : 9, respectively. CONCLUSION: The cetuximab and cisplatin-conjugated gold nanodrug complex has a great potential to increase cytotoxicity and overcome resistance to radiotherapy, in the treatment of oral cavity cancer.


Assuntos
Cetuximab/uso terapêutico , Nanopartículas Metálicas/uso terapêutico , Neoplasias Bucais/tratamento farmacológico , Radiossensibilizantes/uso terapêutico , Cetuximab/farmacologia , Cisplatino/farmacologia , Cisplatino/uso terapêutico , Ouro , Humanos , Boca , Neoplasias Bucais/patologia , Radiossensibilizantes/farmacologia
2.
Turk J Med Sci ; 50(1): 271-276, 2020 02 13.
Artigo em Inglês | MEDLINE | ID: mdl-31742371

RESUMO

Background/aim: Natural products are popular insights for researchers to investigate promising anti-cancer agents since some of these substances have lesser adverse effects restricting the treatment than traditional chemotherapeutic agents. A well-known monoterpene Carvacrol, widely consumed in Mediterranean cuisine and lower risks of cancer, has efficient anticancer effects. However, the mechanism of action is yet to be discovered. Materials and methods: The investigation aims to illuminate a new perceptive in the role of this substance on colorectal cancer treatment, by the means of differences in a well-defined range of soluble factors. Carvacrol effect on both HT-29 and HCT-116 cell lines was evaluated on proliferation and the IC50 values were calculated by the RTCA xCELLigence device. Then MAGPIX assay was performed to obtain the changes in soluble factors of the cell lines. Results: The Multiplexing assay suggests some of these factors were altered in favor of surviving and proliferation in aggressive cell line HCT-116 whereas they were altered against these characters in HT-29, were correlated with the increased IC50 concentration of HCT- 116 in carvacrol treatment. Conclusion: The current study indicates that differences in the levels of these soluble factors could modulate the anticancer effect related to carvacrol.


Assuntos
Neoplasias Colorretais/tratamento farmacológico , Cimenos/farmacologia , Proliferação de Células/efeitos dos fármacos , Neoplasias Colorretais/química , Neoplasias Colorretais/patologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/análise , Células HCT116 , Células HT29 , Humanos , Leptina/análise , Prolactina/análise , Fator de Crescimento Transformador alfa/análise , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...